Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006;10(6):R178.
doi: 10.1186/cc5133.

Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials

Sandro B Rizoli  1 , Kenneth D Boffard, Bruno Riou, Brian Warren, Philip Iau, Yoram Kluger, Rolf Rossaint, Michael Tillinger; NovoSeven Trauma Study Group
Affiliations
Randomized Controlled Trial

Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials

Sandro B Rizoli et al. Crit Care. 2006.

Abstract

Introduction: We conducted a post-hoc analysis on the effect of recombinant factor VIIa (rFVIIa) on coagulopathic patients from two randomized, placebo-controlled, double-blind trials of rFVIIa as an adjunctive therapy for bleeding in patients with severe trauma.

Methods: Blunt and penetrating trauma patients were randomly assigned to rFVIIa (200 + 100 + 100 microg/kg) at 0, 1, and 3 hours after transfusion of 8 units of red blood cells (RBCs) or to placebo. Subjects were monitored for 48 hours post-dosing and followed for 30 days. Coagulopathy was retrospectively defined as transfusion of fresh frozen plasma (FFP) (>1 unit of FFP per 4 units of RBCs), FFP in addition to whole blood, and transfusion of platelets and/or cryoprecipitate.

Results: Sixty rFVIIa-treated and 76 placebo subjects were retrospectively identified as being coagulopathic. No significant differences were noted in baseline characteristics. The rFVIIa-treated coagulopathic subgroup consumed significantly less blood product: RBC transfusion decreased by 2.6 units for the whole study population (P = 0.02) and by 3.5 units among patients surviving more than 48 hours (P < 0.001). Transfusion of FFP (1,400 versus 660 ml, P < 0.01), platelet (300 versus 100 ml, P = 0.01), and massive transfusions (29% versus 6%, P < 0.01) also dropped significantly. rFVIIa reduced multi-organ failure and/or acute respiratory distress syndrome in the coagulopathic patients (3% versus 20%, P = 0.004), whereas thromboembolic events were equally present in both groups (3% versus 4%, P = 1.00).

Conclusion: Coagulopathic trauma patients appear to derive particular benefit from early adjunctive rFVIIa therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trial profile. The figure shows the number of penetrating and blunt trauma patients eligible in the two groups (placebo and recombinant activated factor VII [rFVIIa]), the exclusion of patients because of traumatic brain injury (TBI) and insufficient data concerning the coagulopathic state, and the number of patients finally adjudicated to the placebo and rFVIIa analysis. RBC, red blood cells.
Figure 2
Figure 2
Comparison of the proportion of patients (all coagulopathic patients as well as coagulopathic patients surviving more than 48 hours) requiring massive transfusion. Massive transfusion was defined as more than 12 red blood cell (RBC) units within 48 hours of the first dose, which equals more than 20 units of RBCs (inclusive of the 8 pre-dose units) in the placebo and recombinant activated factor VII (rFVIIa) groups.
See this image and copyright information in PMC

References

    1. Hoyt DB. A clinical review of bleeding dilemmas in trauma. Semin Hematol. 2004;41(1 Suppl 1):40–43. doi: 10.1053/j.seminhematol.2003.11.009. - DOI - PubMed
    1. Sauaia A, Moore FA, Moore EE, Moser KS, Brennan R, Read RA, Pons PT. Epidemiology of trauma deaths: a reassessment. J Trauma. 1995;38:185–193. - PubMed
    1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349:1269–1276. doi: 10.1016/S0140-6736(96)07493-4. - DOI - PubMed
    1. Peden M, McGee K, Sharma G. The Injury Chart Book: A Graphical Overview of the Global Burden of Injuries. Geneva: World Health Organization; 2002.
    1. WHO report 2003: The World Health Report 2003 'Shaping the Future' http://www.who.int

Publication types